Drug intelligence / Profile preview

LP-00D

Development stage: Preclinical
Lead developer: Longbio Pharma
Modality: Bispecific Antibodies → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics, Fc-Fusion Proteins → Carrier/Scaffold Proteins → Recombinant Proteins and Enzymes

Overview

LP-00D is an early-stage therapeutic candidate being developed by Longbio Pharma. It is characterized as a bi-functional antibody or fusion protein designed to target the complement system. While the specific molecular targets are currently undisclosed, the drug is intended for the treatment of various complement-mediated diseases. LP-00D represents part of Longbio Pharma's broader portfolio of multi-specific biologics aimed at modulating immune and inflammatory pathways, following the company's strategy of developing multi-functional biologics for complement and allergic indications.

Beyond the preview

Go deeper on LP-00D.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on LP-00D.

Explore the full profile